New immune cell therapy takes on tough lung cancer
NCT ID NCT07246304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called TC-D101 CAR-T for people with a specific type of advanced small cell lung cancer that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer cells, and is given after a short course of chemotherapy. The main goals are to check safety and find the best dose, with a secondary look at whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TC-D101 CAR-T cells (a type of immune cell therapy) given after chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could point toward a new treatment option for people with a hard-to-treat form of lung cancer that has not responded to standard therapies.
- What could go wrong
- This is a very early (Phase 1) and small trial with only 24 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Jinling Hospital
RECRUITINGNanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental combo aims to tackle Treatment-Resistant cancers
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas